Advanced Filters
noise

Cardiac Disease Clinical Trials

A listing of Cardiac Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,879 clinical trials
M Marek Sramko, MD, PhD

Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure

This study will evaluate the feasibility and safety of achieving therapeutic concentrations of beta-hydroxybutyrate using continuous infusion of D-beta-hydroxybutyrate monoester administered via a nasogastric tube in patients with acutely decompensated heart failure with reduced left ventricular ejection fraction.

18 years of age All Phase 4
J Jinzhou Zhang, Doctorate

Myocardialbridge Bypass Graft Surgery Efficacy Verification

Myocardial Bridge Bypass Graft surgery is introduced to relieve the unmedical symptoms of patients with long-segment or deep myocardial bridge, clinical outcomes will be collected to verify the effectiveness of the surgery.

18 - 80 years of age All Phase N/A
J Jung-Tae Byeon

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

The previous Mono Antiplatelet and Colchicine Therapy (MACT) pilot study (NCT04949516) demonstrated that it was feasible to discontinue aspirin therapy and administer low-dose colchicine on the day after percutaneous coronary intervention (PCI) in addition to potent P2Y12 inhibitors in patients with acute coronary syndrome (ACS). However, the efficacy and safety …

20 - 90 years of age All Phase 4

High Sensitive C-reactive Protein to Albumin Ratio in Acute Coronary Syndrome

assess the use of hs- C-reactive protein to albumin ratio (hs-CAR) in prediction of in-hospital short-term major adverse cardiac events (MACEs) in acute coronary syndrome (ACS) patients

18 years of age All Phase N/A
M Marion AUDIE

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

Congenital heart defects (CHD), as the leading cause of birth defects, affect 12 million people globally and approximately 41,000 newborns each year in Europe. CHD presents a significant public health concern due to its association with high morbidity and mortality rates across the lifespan. Over 50% of infants born with …

years of age All Phase N/A
S Sajiny John

A Prospective Research Investigation of Ischemia Using MCG

PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.

18 years of age All Phase N/A

Customization of Cardiac Readaptation Based on Force-velocity Profile and Heart Rate Variability

Cardiac readaptation aims to mitigate cardiovascular risks and enhance the quality of life among coronary patients. Our research laboratory has an international expertise in training optimization in top-athletes and a previous study has demonstrated the efficacy of optimizing cardiac rehabilitation through the power-force-velocity profile (PFVP). The findings exhibited significant improvements …

18 years of age All Phase N/A
G Gonzalo Martinez, Dr.

Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome

This randomized clinical trial will determine the treatment effect of colchicine (1.5 mg loading dose and 0.5 mg daily thereafter) for 6 weeks on microvascular coronary reperfusion and infarct size in patients with acute coronary syndrome.

18 years of age All Phase 2

POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy

The goal of this pilot clinical trial is to test the safety and effectiveness of genotype-guided clopidogrel monotherapy in patients presenting with Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) who have undergone successful Percutaneous Coronary Intervention (PCI). The main questions it aims to answer are: Is genotype-guided clopidogrel monotherapy effective in …

18 years of age All Phase 2
T Tamara Wakhisi, CCRP

AngelMed Guardian® System PMA Post Approval Study

500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care. Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.

21 years of age All Phase N/A

Simplify language using AI